"With the top two generic manufacturers, Teva and Mylan NV ( MYL ) only making up 13% and 11% of the U.S. generic drug market, respectively, there is still a lot of room for growth," Goldman Sachs writes, citing comments by Mylan CEO Heather Bresch. Goldman added, "President of Impax Laboratories Inc. ( IPXL ) Robert Stewart, echoed this view stating that further consolidation will need to happen in the near term for the industry to stay in lockstep with buyer consolidation -- moreover, there are distressed assets that could present opportunistic buying opportunities." --Brian Sozzi contributed to this report